Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge - Wikidata - awgldk - TriplyDB

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

http://www.wikidata.org/entity/Q34058118

about

Infectious Mononucleosis Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy Progress, prospects, and problems in Epstein-Barr virus vaccine development.Modeling EBV infection and pathogenesis in new-generation humanized mice.Epstein-barr virus vaccines.Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome.Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site The need and challenges for development of an Epstein-Barr virus vaccine High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.Epstein-Barr virus and multiple sclerosis: association or causation?Nonhuman primate models for Epstein-Barr virus infection.RNA-based viral vectors.EBV glycoproteins: where are we now?Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.

P2860

Q26783692-950B1372-F6D5-475F-9DEB-6C12D1C71615 Q30878158-2456752A-C6F6-4A27-930E-2EA8DF16B057 Q33812640-C75C4D8B-A358-4137-8A1A-5A0D1E47C669 Q35040650-FCCA1B41-E389-4C63-9844-4AF518B73DF1 Q35053650-FCAD9CBE-19E5-4088-8240-F8E309E54633 Q35994831-0C85C68E-A5DE-474F-B382-FADF4BAB546B Q36383086-60BBEEF9-516E-454F-B37D-6CE50609A7C4 Q36590540-39913B84-7AE2-4E56-A25A-09FA60BD6951 Q36795587-41A2631C-1BC0-4033-8B91-D925DEB6CA2E Q37100066-32E4E3B2-70A6-43EA-8822-64D212270D50 Q37493561-314EBC6F-912E-4973-BA09-90EA08325A83 Q38085337-FD536A6F-2B38-495C-A5DE-EC33D9FE1D37 Q38096649-EA7B8096-ED22-4264-A256-BD71470E549F Q38266413-A395F487-2FB9-4B8D-90B2-61BFBA7CE462 Q38912277-C2B26293-0AC4-4DC0-B156-A91FE6F8F414 Q39170011-B901B3EB-EAFD-4D74-8E07-715D0C3E9B1A Q40967391-64117CA9-4778-4B42-A1EC-42F5CAACA393

P2860

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

http://www.wikidata.org/entity/Q34058118

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@ast

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@en

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@nl

type

label

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@ast

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@en

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@nl

prefLabel

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@ast

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@en

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@nl

P1433

Q34058118-3AF8F77C-1B03-4A44-946E-8F458091CBF1

P1476

Q34058118-3A83B669-4EE7-4643-BCAB-437095DC9C6A

P2093

Q34058118-1BA817FB-5B69-4EA4-8F54-671C249DAB17

Q34058118-2F057EBC-F88A-411D-AAEB-151969F37196

Q34058118-2F51D240-9B35-4DC7-A30A-926021498E41

Q34058118-61215274-2562-45A8-A103-EC24074DF36E

Q34058118-B049A36D-94F3-4126-9D7D-B25E74ABE837

Q34058118-B422A172-1E03-4860-A246-6B7629E9CBD1

Q34058118-C53D3FF5-48DA-43FA-B623-D12EF1E0CDE6

Q34058118-D5BA6812-989C-4ACA-90B8-BE30402BAFC6

P2860

Q34058118-06C417D9-374A-4B0C-8218-36EC12022D2C

Q34058118-0A592509-1997-4D89-8A98-C1375757D2C9

Q34058118-0E263297-6E17-4EBD-8F8D-3A46B04EF79D

Q34058118-129E7244-09A1-4646-90C2-472B7D9213E4

Q34058118-2026938F-1B19-48A5-B0DE-0B956F6B429C

Q34058118-2E49F08D-552C-4536-B4CE-2F44639BF6A4

Q34058118-30C12DE8-F1B7-4971-8107-BF6175AAE463

Q34058118-3204B8BD-3450-4232-8619-BB6E60F9F9FF

Q34058118-3F702899-F09E-4B0F-B0EE-5B793DF6CA00

Q34058118-494A1601-A58B-4EC4-B19E-3B35CA12BE2B

P304

Q34058118-E59E80DB-4749-4336-9885-A739B4B1D9DB

P31

Q34058118-B3A481F8-975D-421C-8ED7-97B36DB64B7E

P356

Q34058118-E172BCC4-17E5-4837-9839-5600CAF7C721

P433

Q34058118-95BFBB40-834B-4BFA-8A27-3B334536159C

P478

Q34058118-CF863489-E821-49A4-9479-9C6FACAFF386

P577

Q34058118-8FE223EF-F82E-47BF-9C47-988AAC90646C

P5875

Q34058118-D8977E08-FB14-480E-A180-C60D9B57A97F

P698

Q34058118-1DD26057-F4C3-44F5-BC14-56B65F8F497E

P921

Q34058118-C6F442F9-481F-44D6-900C-5DB7D969AFAC

P932

Q34058118-BA16F77C-5F4F-4A21-B0A4-C5313F864BD9

P356

JOURNAL.PPAT.1002308

P1433

P1476

Soluble rhesus lymphocryptovir ...... ted with virus after challenge

@en

P2093

J Jason Bowman

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Cohen

http://www.w3.org/2001/XMLSchema#string

Junji Sashihara

http://www.w3.org/2001/XMLSchema#string

Kurt Kamrud

http://www.w3.org/2001/XMLSchema#string

Peter D Burbelo

http://www.w3.org/2001/XMLSchema#string

Tammy Krogmann

http://www.w3.org/2001/XMLSchema#string

V McNeil Coffield

http://www.w3.org/2001/XMLSchema#string

Yo Hoshino

http://www.w3.org/2001/XMLSchema#string

P2860

Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model.

Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15

Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis

An animal model for acute and persistent Epstein-Barr virus infection

MHC class I genes in a New World primate, the cotton-top tamarin (Saguinus oedipus), have evolved by an active process of loci turnover.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical.

Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

P304

e1002308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1002308

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51746576

http://www.w3.org/2001/XMLSchema#string

P698

22028652

http://www.w3.org/2001/XMLSchema#string

P921

P932

3197588

http://www.w3.org/2001/XMLSchema#string